[go: up one dir, main page]

EP1985285A3 - Compositions and methods for treating lymphoma - Google Patents

Compositions and methods for treating lymphoma Download PDF

Info

Publication number
EP1985285A3
EP1985285A3 EP08003804A EP08003804A EP1985285A3 EP 1985285 A3 EP1985285 A3 EP 1985285A3 EP 08003804 A EP08003804 A EP 08003804A EP 08003804 A EP08003804 A EP 08003804A EP 1985285 A3 EP1985285 A3 EP 1985285A3
Authority
EP
European Patent Office
Prior art keywords
methods
compositions
lymphoma
treating lymphoma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08003804A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1985285A2 (en
Inventor
Clive T. R. Burge
James H. Goldie
Murray S. Webb
Patricia M BioLoma Consulting Inc. Logan
Andreas H Hygeia Hospital & Harvard Medical International Sarris
Fernando Cabanillas
Lawrence D. Mayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Talon Therapeutics Inc
Original Assignee
Hana Biosciences Inc
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hana Biosciences Inc, University of Texas System, University of Texas at Austin filed Critical Hana Biosciences Inc
Priority to EP10011105.3A priority Critical patent/EP2266537B1/en
Priority to DK10011105.3T priority patent/DK2266537T3/en
Publication of EP1985285A2 publication Critical patent/EP1985285A2/en
Publication of EP1985285A3 publication Critical patent/EP1985285A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP08003804A 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma Withdrawn EP1985285A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP10011105.3A EP2266537B1 (en) 1999-04-01 2000-03-31 Compositions for treating cancer
DK10011105.3T DK2266537T3 (en) 1999-04-01 2000-03-31 Compositions for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
EP00920004A EP1169021B1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP00920004A Division EP1169021B1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP10011105.3A Division EP2266537B1 (en) 1999-04-01 2000-03-31 Compositions for treating cancer

Publications (2)

Publication Number Publication Date
EP1985285A2 EP1985285A2 (en) 2008-10-29
EP1985285A3 true EP1985285A3 (en) 2009-08-12

Family

ID=26825635

Family Applications (3)

Application Number Title Priority Date Filing Date
EP10011105.3A Expired - Lifetime EP2266537B1 (en) 1999-04-01 2000-03-31 Compositions for treating cancer
EP08003804A Withdrawn EP1985285A3 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma
EP00920004A Expired - Lifetime EP1169021B1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP10011105.3A Expired - Lifetime EP2266537B1 (en) 1999-04-01 2000-03-31 Compositions for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP00920004A Expired - Lifetime EP1169021B1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Country Status (14)

Country Link
EP (3) EP2266537B1 (ja)
JP (3) JP2002541088A (ja)
AT (1) ATE442839T1 (ja)
AU (1) AU777572B2 (ja)
BR (1) BRPI0009448B8 (ja)
CA (1) CA2366787C (ja)
CY (1) CY1109641T1 (ja)
DE (1) DE60042968D1 (ja)
DK (2) DK2266537T3 (ja)
ES (2) ES2333400T3 (ja)
HK (1) HK1152246A1 (ja)
IL (4) IL145720A0 (ja)
PT (1) PT1169021E (ja)
WO (1) WO2000059473A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2266537T3 (en) * 1999-04-01 2014-12-15 Talon Therapeutics Inc Compositions for treating cancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ATE440593T1 (de) * 2001-03-27 2009-09-15 Phares Pharm Res Nv Verfahren und zusammensetzung zur solubilisierung einer biologisch wirksamen verbindung mit geringer wasserlíslichkeit
CN103494817A (zh) * 2002-05-17 2014-01-08 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
BRPI0513007A (pt) * 2004-07-09 2008-04-22 Schering Ag terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
US8877803B2 (en) 2007-09-10 2014-11-04 Boston Biomedical, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
CR20180483A (es) 2008-03-18 2018-12-05 Genentech Inc COMBINACIONES DE UN CONJUNGADO ANTICUERPO-FÁRMACO ANTI-HER2 Y AGENTES QUIMIOTERAPÉUTICOS (Divisional 11678)
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
JP6419710B2 (ja) * 2012-11-20 2018-11-07 スペクトラム ファーマシューティカルズ 治療的使用のためのリポソーム封入ビンクリスチンの調製のための改良法
EP2948132B1 (en) * 2013-01-24 2020-08-19 Memorial Sloan Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
DK2266537T3 (en) * 1999-04-01 2014-12-15 Talon Therapeutics Inc Compositions for treating cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties

Also Published As

Publication number Publication date
ES2524141T3 (es) 2014-12-04
ATE442839T1 (de) 2009-10-15
IL145720A0 (en) 2002-07-25
IL212390A (en) 2014-08-31
BRPI0009448B8 (pt) 2021-05-25
DE60042968D1 (de) 2009-10-29
CY1109641T1 (el) 2014-08-13
JP2002541088A (ja) 2002-12-03
BRPI0009448B1 (pt) 2018-09-11
EP1169021B1 (en) 2009-09-16
AU4060600A (en) 2000-10-23
JP2015071631A (ja) 2015-04-16
AU777572B2 (en) 2004-10-21
EP1985285A2 (en) 2008-10-29
JP2012158602A (ja) 2012-08-23
CA2366787C (en) 2013-03-12
EP2266537A2 (en) 2010-12-29
CA2366787A1 (en) 2000-10-12
IL145720A (en) 2011-05-31
EP1169021A1 (en) 2002-01-09
IL212389A0 (en) 2011-06-30
PT1169021E (pt) 2009-11-18
DK2266537T3 (en) 2014-12-15
EP2266537A3 (en) 2012-02-22
EP2266537B1 (en) 2014-09-03
HK1152246A1 (en) 2012-02-24
IL212389A (en) 2015-07-30
WO2000059473A1 (en) 2000-10-12
ES2333400T3 (es) 2010-02-22
IL212390A0 (en) 2011-06-30
DK1169021T3 (da) 2010-01-11
BR0009448A (pt) 2002-01-08
JP5981214B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
EP1985285A3 (en) Compositions and methods for treating lymphoma
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
FR13C0062I1 (ja)
EP0993831A3 (en) Compounds and compositions for delivering active agents
WO2000007979A3 (en) Compounds and compositions for delivering active agents
EP1478406A4 (en) COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
NZ333385A (en) Solid oral dosage forms containing 35% of valsartan
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
CA2274338A1 (en) Ziprasidone formulations
AU2595697A (en) Compounds and compositions for delivering active agents
AU1973900A (en) Fuel additive and fuel composition containing the same
AU4322999A (en) Methods and compositions for diagnosing tauopathies
AU3877800A (en) Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
HK1108825A1 (en) Compositions and methods for treating leukemia
BG105256A (en) Muscarinic agonists and antagonists
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU4900797A (en) Conformationally restricted polyamines and their use as antineoplastic agents
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
HUP0105308A3 (en) Eletriptan hydrobromide monohydrate, process for its preparation and pharmaceutical compositions containing the same
CA2398389A1 (en) Method for inhibiting a tumor
AU2001291217A1 (en) Novel compositions and methods for lymphoma and leukemia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080229

AC Divisional application: reference to earlier application

Ref document number: 1169021

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125833

Country of ref document: HK

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20111202

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST

Owner name: TALON THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TALON THERAPEUTICS, INC.

Owner name: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20161103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125833

Country of ref document: HK